Clinical outcomes of lentiviral vector gene therapy for sickle cell disease.

Saved in:
Bibliographic Details
Title: Clinical outcomes of lentiviral vector gene therapy for sickle cell disease.
Authors: Prueksapraopong C; Department of Pediatrics, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA., Fernandes A; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA., Campo Fernandez B; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA., Roy S; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA., Hollis RP; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA., Habtemariam B; Department of Medicine, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA., Pellin D; Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Ceoldo G; Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Lin TY; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Dang TT; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Cornetta K; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Romero Z; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA., Blazar BR; Division of Pediatric Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN., Shah AJ; Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Stanford School of Medicine, Palo Alto, CA., Moore TB; Department of Pediatrics, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA., Sehl M; Department of Medicine, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA., Schiller GJ; Department of Medicine, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA., Kohn DB; Department of Pediatrics, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA.; The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, Los Angeles, CA.
Source: Blood advances [Blood Adv] 2026 Jul 28; Vol. 10 (14), pp. 4991-5002.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2026019869